Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.

In this study, researchers found that serum granulysin levels might serve as a novel marker for disease activity in acute alopecia areata, being significantly associated with broader bald skin areas, poorer prognosis, and co-existing allergic disorders.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.

This research abstract describes alopecia areata as an autoimmune disease causing hair loss due to an inflammatory response mediated by the JAK/STAT signaling pathway. The condition, which affects young people disproportionately, lacks a cure and entails significant psychosocial challenges, despite varied treatment attempts.

This study described cases of alopecia areata occurring after COVID-19 vaccination and highlights management using both topical and systemic therapies.

This meta-analysis found that alopecia areata patients had significantly higher serum levels of IL-6 and TNF-α compared to healthy subjects, indicating a potential role of these cytokines in the condition's pathogenesis.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study reported significant hair regeneration in a 3-year-old with severe alopecia areata after six months of treatment with microneedling and compound betamethasone.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

In this case report, a 7-year-old girl with severe alopecia areata and high baseline IgE levels achieved complete hair regrowth after 48 weeks of dupilumab therapy, with observed decreases in IgE levels and no significant adverse effects beyond a mild initial allergic reaction.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

This case series found that topical janus kinase inhibitors, along with oral fexofenadine and vitamin D supplementation, significantly reduced disease severity in Black pediatric patients with alopecia areata, demonstrating substantial hair regrowth and minimal adverse side effects.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

This review explores low-level light therapy's potential as a noninvasive treatment for various forms of alopecia, noting its promising results in hair regrowth and density but highlighting the need for standardized protocols and further research.

In this study, topical and intralesional vitamin D3 and its analogs were found to be effective and safe treatments for mild-to-moderate alopecia areata, achieving a 53.75% success rate, though intralesional vitamin D3 was less effective than other treatments like corticosteroids.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

This article reviews existing research on the treatment of alopecia areata using growth factors and microneedling, reporting that these methods show promise in promoting hair growth without major adverse effects, but emphasizes the need for additional large-scale studies to confirm their efficacy and safety.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This study suggests that platelet-rich plasma is a safe and effective treatment for alopecia areata, showing superior treatment response compared to triamcinolone acetonide and placebo, with primarily minor side effects.

In this study, researchers found a significant association between attention-deficit/hyperactivity disorder stimulant medications and alopecia universalis in children, although this finding was based on a small sample size.

This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.

This study found that gene expression of CD70 and CD27 was higher in alopecia areata lesions and correlated with increased disease severity and activity.